IN2014DN06850A - - Google Patents

Download PDF

Info

Publication number
IN2014DN06850A
IN2014DN06850A IN6850DEN2014A IN2014DN06850A IN 2014DN06850 A IN2014DN06850 A IN 2014DN06850A IN 6850DEN2014 A IN6850DEN2014 A IN 6850DEN2014A IN 2014DN06850 A IN2014DN06850 A IN 2014DN06850A
Authority
IN
India
Prior art keywords
ch2oh
cooh
carbon atoms
present
invention regards
Prior art date
Application number
Inventor
Valle Francesco Della
Valle Maria Federica Della
Gabriele Marcolongo
Marzo Vincenzo Di
Salvatore Cuzzocrea
Original Assignee
Epitech Group Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epitech Group Srl filed Critical Epitech Group Srl
Publication of IN2014DN06850A publication Critical patent/IN2014DN06850A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/12—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals containing only hydrogen and carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/10—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention regards compositions and methods for the modulation of amidases capable of hydrolysing N-acylethanolamines useable in the therapy of inflammatory diseases. In particular, the present invention regards a compound of general formula (I): enantiomers, diastereoisomers, racemes and mixtures, polymorphs, salts, solvates thereof, wherein: (a) R is a linear alkyl radical having 13 to 19 carbon atoms or alkenyl radical having 13 to 19 carbon atoms carrying a double bond; (b) X is 0 or S; (c) Y is a 2 or 3 carbon atom alkylene residue, optionally substituted with one or two groups equal or different from each other and selected from among the group consisting of: -CH3, -CH2OH, -COOCH3, -COOH. Y may preferably be: -CH2-CH2-, -CH2-CH2-CH2-, CH (CH3) -CH2-, -CH2-CH (CH3) -, -CH2-C (CH ) 2-, -CH2-CH (CH2OH) -, -CH2-C ( (CH2OH) 2) -, -CH=CH-, -CH2-CH (COOCH ) -, -CH2-CH (COOH) -, for use as a medicine.
IN6850DEN2014 2012-02-17 2012-02-17 IN2014DN06850A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT2012/000050 WO2013121449A1 (en) 2012-02-17 2012-02-17 Compositions and methods for the modulation of specific amidases for n-acylethanolamines for use in the therapy of inflammatory diseases

Publications (1)

Publication Number Publication Date
IN2014DN06850A true IN2014DN06850A (en) 2015-06-26

Family

ID=46000230

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6850DEN2014 IN2014DN06850A (en) 2012-02-17 2012-02-17

Country Status (14)

Country Link
US (1) US9512091B2 (en)
EP (1) EP2814489B1 (en)
JP (1) JP5982016B2 (en)
KR (1) KR101854879B1 (en)
CN (1) CN104244948B (en)
AR (1) AR090066A1 (en)
AU (1) AU2012327209B2 (en)
BR (1) BR112014020992B1 (en)
CA (1) CA2864259C (en)
DK (1) DK2814489T3 (en)
ES (1) ES2648188T3 (en)
IN (1) IN2014DN06850A (en)
PT (1) PT2814489T (en)
WO (1) WO2013121449A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2772252T3 (en) * 2014-03-21 2020-07-07 Epitech Group S P A Ophthalmic, intra-articular or intravesical preparations containing N-acyl-ethanolamines
PL2965765T3 (en) * 2014-07-08 2019-11-29 Epitech Group S P A Use of adelmidrol in the treatment of epithelial dysfunctions
US20180171389A1 (en) * 2015-06-16 2018-06-21 Murdoch Childrens Research Institute Method of treating crohn's disease
CN108348468A (en) * 2015-08-11 2018-07-31 Eyesiu医疗股份有限公司 PEGylated Lipid Nanoparticles with Bioactive Lipophilic Compounds
EP3520785B1 (en) * 2016-10-09 2024-07-17 Shenzhen Eulikan Biotechnology Co., Ltd. Uses of bacteriostatic agent formula in preparing composition for vaginal use and composition for vaginal use
US10143639B2 (en) * 2017-03-22 2018-12-04 William Robert McDaniel Use of adelmidrol and other topical or oral cannabinomimetic or aliamide mast cell inhibitors to treat dermatoheliosis, seborrheic keratoses, and androgenetic alopecia
PH12018000077B1 (en) 2017-07-05 2021-07-09 Frimline Private Ltd A pharmaceutical composition for neuropathic pain
PH12018000227A1 (en) 2017-09-05 2019-03-11 Frimline Private Ltd A pharmaceutical composition for improving or preventing progression of chronic kidney disease
EP3574899A1 (en) * 2018-05-28 2019-12-04 Université de Bourgogne Oleic acid derivatives, pharmaceutical composition or food composition comprising said oleic acid derivatives, and their uses
FR3098394B1 (en) * 2019-07-12 2022-07-08 Expanscience Lab Composition comprising at least one oxazoline for inhibiting the growth of yeast of the genus Malassezia involved in particular in cradle cap
IT202200017820A1 (en) * 2022-08-30 2024-03-01 Unifarco S P A Nutraceutical tablet containing palmitoylethanolamide
CN118125936B (en) * 2022-11-25 2025-10-03 南京清普生物科技有限公司 N-acylethanolamide derivatives and their preparation methods and applications

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2368075A (en) * 1943-09-11 1945-01-23 Commercial Solvents Corp Astringent preparations
US2450806A (en) * 1945-12-07 1948-10-05 Gulf Research Development Co Rust preventive chromium compounds and compositions containing them
US2547493A (en) * 1949-12-01 1951-04-03 Rohm & Haas Imido-esters of diels-alder adducts and process for producing same
US2965459A (en) * 1958-03-03 1960-12-20 Standard Oil Co Gasoline containing borated oxazolines
US3389145A (en) * 1965-10-24 1968-06-18 Katz Jacob Fatty oxazoline surfactants and a process for their preparation
US3648847A (en) * 1969-01-07 1972-03-14 Reichhold Chemicals Inc Filter aid conditioners
US3886128A (en) * 1973-10-15 1975-05-27 Commercial Solvents Corp Oxazoline emulsifier in polymerization of styrene and butadiene
US3920567A (en) 1974-12-27 1975-11-18 Exxon Research Engineering Co Novel oxazoline-alkyl acid phosphate adducts useful as ashless antiwear additives
JPS5283321A (en) * 1975-12-27 1977-07-12 Takeshi Tomiyama Method of manufacturing geranyl farnesyl acetate
US4049819A (en) * 1976-02-09 1977-09-20 Imc Chemical Group, Inc. Method of combatting microorganisms employing substituted oxazolines
US4224172A (en) * 1978-12-04 1980-09-23 Mobil Oil Corporation Oil-soluble adducts of benzotriazole and oxazolines and lubricant compositions containing same
US4477384A (en) * 1981-02-20 1984-10-16 The United States Of America As Represented By The Secretary Of Agriculture Preparation of α-substituted acrylic acids
EP0238210A3 (en) * 1986-03-14 1989-05-24 Imperial Chemical Industries Plc Solid explosive composition
US4876249A (en) * 1987-01-12 1989-10-24 Rajadhyaksha Vithal J Compositions and method comprising heterocyclic compounds containing two heteroatoms
DE3710516A1 (en) * 1987-03-30 1988-10-20 Henkel Kgaa METHOD FOR PRODUCING 2-BENZYL FATTY ACIDS
NZ226043A (en) * 1987-09-23 1991-05-28 Ici Australia Operations Explosive composition: ammonium nitrate prills
DE3824982A1 (en) * 1987-11-10 1989-05-18 Henkel Kgaa 2- (11-HYDROXY-8-HEPTADECENYL- OR 11,8- AND 11,9-HEPTADECADIENYL) OXAZOLIN, AND METHOD FOR THE MANUFACTURE, IF SUCH, OF SUBSTITUTED HOEHERER 2- (ALKYL- AND ALKENYL) -OXAZOLINES
JPH0747636B2 (en) * 1988-12-05 1995-05-24 東レ株式会社 Thermoplastic polyamide resin composition
DE3914155A1 (en) * 1989-04-28 1990-10-31 Henkel Kgaa PROCESS FOR PREPARING 5,6-DIHYDRO-4H-1,3-OXAZINES
DE4104789A1 (en) * 1991-02-16 1992-08-20 Henkel Kgaa Cyclic poly:imino-ethers, useful esp. for prodn. of stoving enamels - comprises reaction of di- and-or poly:isocyanate(s) with special cyclic mono-imino-ethers, esp. 2-alkyl-oxazolines
DE4229020A1 (en) * 1992-09-03 1994-03-10 Henkel Kgaa Prepn. of omega-alkanoyl-amino-alkyl-substd. quat. ammonium salts - by reacting a secondary ammonium salt or a pyridinium salt with an oxazoline or oxazine deriv.
US5698017A (en) * 1996-09-27 1997-12-16 Xerox Corporation Oxazoline hot melt ink compositions
US6462054B1 (en) 2000-03-27 2002-10-08 The Scripps Research Institute Inhibitors of fatty acid amide hydrolase
US6706674B2 (en) * 2001-01-17 2004-03-16 The Andrew Jergens Company Nonaqueous hair styling composition and method of use
FR2834216B1 (en) 2001-12-27 2004-04-30 Pharmascience Lab COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE OXAZOLINE FOR INHIBITING LANGERHAN CELL MIGRATION, AND USES THEREOF
EA008767B1 (en) * 2002-10-08 2007-08-31 Зе Скрипс Ресеч Инститьют Inhibitors of fatty acid amide hydrolase
FR2885128B1 (en) * 2005-04-27 2007-07-06 Expanscience Laboratoires Sa DEPIGMENTING OR LIGHTENING COSMETIC COMPOSITION COMPRISING AT LEAST ONE OXAZOLINE AS AN ACTIVE INGREDIENT DEPIGMENTING OR LIGHTENING
CN101605592B (en) * 2007-02-05 2011-10-12 陶氏环球技术公司 Modified polyamide membrane
US20110184026A1 (en) 2008-06-19 2011-07-28 Boger Dale L C4-substituted alpha-keto oxazoles
WO2011085216A2 (en) * 2010-01-08 2011-07-14 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating parkinson's disease and restless legs syndrome

Also Published As

Publication number Publication date
BR112014020992A2 (en) 2017-06-20
US9512091B2 (en) 2016-12-06
ES2648188T3 (en) 2017-12-29
JP2015511239A (en) 2015-04-16
CN104244948A (en) 2014-12-24
PT2814489T (en) 2017-10-23
EP2814489B1 (en) 2017-08-23
BR112014020992B1 (en) 2021-11-09
AU2012327209B2 (en) 2016-05-19
EP2814489A1 (en) 2014-12-24
CA2864259A1 (en) 2013-08-22
CN104244948B (en) 2016-11-16
WO2013121449A1 (en) 2013-08-22
WO2013121449A8 (en) 2013-12-12
AU2012327209A8 (en) 2015-01-22
KR101854879B1 (en) 2018-05-04
DK2814489T3 (en) 2017-10-30
US20150057269A1 (en) 2015-02-26
AR090066A1 (en) 2014-10-15
AU2012327209A1 (en) 2013-10-31
JP5982016B2 (en) 2016-08-31
KR20140147819A (en) 2014-12-30
CA2864259C (en) 2019-06-11

Similar Documents

Publication Publication Date Title
IN2014DN06850A (en)
RS53679B1 (en) Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases
MY191912A (en) Estolide compositions exhibiting high oxidative stability
AR086958A1 (en) TRPV4 ANTAGONISTS
IN2014DN03483A (en)
MY155133A (en) Compounds having crth2 antagonist activity
TW201129552A (en) Salt and photoresist composition containing the same
IN2014MN01521A (en)
AR085920A1 (en) USEFUL BENZIMIDAZOLIC DERIVATIVES AS ANTITUMOR AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
NZ592228A (en) Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field
JP2017526786A5 (en)
PH12013500893A1 (en) Methods of treatment using lipid compounds
AR080249A1 (en) BRADIQUININA-B1 ANTAGONIST QUALITY COMPOUNDS
MX2016014239A (en) Cleaning composition.
WO2012153825A3 (en) Skin external preparation and method of producing same
IN2014MN00411A (en)
IN2014DN02947A (en)
EA201590315A1 (en) MEANS AND METHOD OF TREATMENT OF SOLID TUMORS
TW201129532A (en) Salt and photoresist composition containing the same
IN2014MN00850A (en)
BR112014015430A2 (en) ophthalmic formulation
AR077429A1 (en) HYDROXIASENAPINA COMPOUNDS ITS DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE SAME
IN2012DN01251A (en)
MX2015002705A (en) Pyridinone compounds for use in photodynamic therapy.
SE1100784A1 (en) New phosphate compound